Steris (STE)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$209.44-2.76%
Close 2026-07-08 · 1-day change
Reading STE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track STE free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading STE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track STE free→QuarterlyIQ Insights · STE
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $209.44. As of 2026-07-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $209 STE trades at 21× p/e, below its 36× p/e peer median, but our blended $203 fair value sits below the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 29% over what the business is worth with no growth; closing that gap needs roughly 6.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $8.36/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $452.96 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $463.78 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $44.10 | — | — | TTM | high |
| graham number | 12M | $129.24 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $76.82 | 6.0 | 15.41 | TTM | high |
| Peer P/FCF | 12M | $232.27 | 23.6 | 9.86 | TTM | high |
| Peer P/E | 12M | $364.78 | 35.9 | 10.17 | TTM | high |
| Peer P/S | 12M | $163.24 | 2.7 | 60.20 | TTM | high |
| PEG | 12M | $245.01 | 24.1 | 10.17 | TTM | high |
| residual income | 12M | $89.84 | — | — | TTM | high |
| Own P/E history | 12M | $241.20 | 23.7 | 10.17 | TTM | high |
| triangulated | 12M | $360.37 | 35.9 | 10.05 | Triangulated | high |
| Peer P/FCF | 3Y | $353.25 | 23.6 | 15.00 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $483.72 | 35.9 | 13.49 | Analyst | medium |
| Peer P/S | 3Y | $206.27 | 2.7 | 76.07 | Analyst | medium |
| PEG | 3Y | $324.91 | 24.1 | 13.49 | Analyst | medium |
| Own P/E history | 3Y | $319.85 | 23.7 | 13.49 | Analyst | medium |
| Mgmt guidance | 5Y | $21.15 | 35.9 | 0.59 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $467.17 | 23.6 | 19.84 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $563.59 | 35.9 | 15.71 | Analyst | high |
| Peer P/S | 5Y | $240.32 | 2.7 | 88.63 | Analyst | high |
| PEG | 5Y | $378.55 | 24.1 | 15.71 | Analyst | high |
| Own P/E history | 5Y | $372.66 | 23.7 | 15.71 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.